Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ACUS NYSE:ADCT OTCMKTS:NEVPF OTCMKTS:RHHBY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACUSAcusphere$0.00$0.00▼$0.00N/AN/AN/AN/AADCTADC Therapeutics$1.18+2.2%$1.73$0.78▼$4.98$149.45M1.871.08 million shs720,877 shsNEVPFAbliva AB (publ)$0.03$0.03$0.01▼$0.04$11.28M-1.184,445 shsN/ARHHBYRoche$54.70$51.48$37.51▼$60.85$348.47B0.51.97 million shs3.51 million shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACUSAcusphere0.00%0.00%0.00%0.00%-90.00%ADCTADC Therapeutics0.00%-13.28%+13.53%-68.80%-64.23%NEVPFAbliva AB (publ)0.00%0.00%0.00%0.00%0.00%RHHBYRoche0.00%+6.01%+5.72%+6.79%+33.45%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACUSAcusphere$0.00$0.00▼$0.00N/AN/AN/AN/AADCTADC Therapeutics$1.18+2.2%$1.73$0.78▼$4.98$149.45M1.871.08 million shs720,877 shsNEVPFAbliva AB (publ)$0.03$0.03$0.01▼$0.04$11.28M-1.184,445 shsN/ARHHBYRoche$54.70$51.48$37.51▼$60.85$348.47B0.51.97 million shs3.51 million shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACUSAcusphere0.00%0.00%0.00%0.00%-90.00%ADCTADC Therapeutics0.00%-13.28%+13.53%-68.80%-64.23%NEVPFAbliva AB (publ)0.00%0.00%0.00%0.00%0.00%RHHBYRoche0.00%+6.01%+5.72%+6.79%+33.45%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACUSAcusphere 0.00N/AN/AN/AADCTADC Therapeutics 2.33Hold$6.25431.91% UpsideNEVPFAbliva AB (publ) 0.00N/AN/AN/ARHHBYRoche 2.27Hold$51.50-5.85% DownsideCurrent Analyst Ratings BreakdownLatest RHHBY, NEVPF, ACUS, and ADCT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2026ADCTADC Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/14/2026RHHBYRoche Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell7/6/2026RHHBYRoche HSBCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold6/8/2026ADCTADC Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral6/4/2026ADCTADC Therapeutics StephensSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$5.006/4/2026ADCTADC Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight6/4/2026ADCTADC Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Sector Perform$6.00 ➝ $2.005/5/2026ADCTADC Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$6.005/5/2026ADCTADC Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.00(Data available from 7/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACUSAcusphereN/AN/AN/AN/AN/AN/AADCTADC Therapeutics$81.36M1.84N/AN/A($1.50) per share-0.78NEVPFAbliva AB (publ)$10K1,128.43N/AN/A$0.02 per share1.40RHHBYRoche$76.45B4.56$3.60 per share15.19$7.18 per share7.62Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACUSAcusphereN/AN/AN/AN/AN/AN/AN/AN/AN/AADCTADC Therapeutics-$142.62M-$1.05N/AN/AN/A-173.02%N/A-44.70%8/11/2026 (Estimated)NEVPFAbliva AB (publ)-$9.01MN/AN/AN/AN/AN/A-117.92%-102.44%N/ARHHBYRoche$15.55BN/AN/A16.483.98N/AN/AN/AN/ALatest RHHBY, NEVPF, ACUS, and ADCT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2026Q2 2026ADCTADC Therapeutics-$0.19N/AN/AN/A$18.89 millionN/A5/4/2026Q1 2026ADCTADC Therapeutics-$0.19-$0.21-$0.02-$0.21$19.99 million$20.85 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACUSAcusphereN/AN/AN/AN/AN/AADCTADC TherapeuticsN/AN/AN/AN/AN/ANEVPFAbliva AB (publ)N/AN/AN/AN/AN/ARHHBYRoche$0.971.77%N/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACUSAcusphereN/AN/AN/AADCTADC TherapeuticsN/A4.094.02NEVPFAbliva AB (publ)N/A7.997.99RHHBYRoche0.721.381.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACUSAcusphereN/AADCTADC Therapeutics41.10%NEVPFAbliva AB (publ)N/ARHHBYRocheN/AInsider OwnershipCompanyInsider OwnershipACUSAcusphere4.60%ADCTADC Therapeutics5.40%NEVPFAbliva AB (publ)N/ARHHBYRocheN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACUSAcusphere118N/AN/ANot OptionableADCTADC Therapeutics310127.19 million120.32 millionOptionableNEVPFAbliva AB (publ)8403.01 millionN/ANot OptionableRHHBYRoche103,2496.37 billionN/ANot OptionableRHHBY, NEVPF, ACUS, and ADCT HeadlinesRecent News About These CompaniesAristotle Capital Management LLC Decreases Stock Holdings in Roche Holding AG $RHHBYJuly 25 at 3:06 AM | marketbeat.comCHMP recommends EU approval of Roche’s Susvimo, the first continuous delivery treatment for neovascular age-related macular degeneration (nAMD)July 24 at 7:43 PM | taiwannews.com.twTRoche receives FDA clearance for cobas BV/CV assay, expanding women’s health diagnosticsJuly 24 at 7:43 PM | msn.comHow Roche unexpectedly buoyed IBD stock of the day, TG TherapeuticsJuly 24 at 7:43 PM | msn.comRoche Holding AG (RHHBY) Q2 2026 Earnings Call TranscriptJuly 24 at 3:00 PM | seekingalpha.comRoche jumps despite reiterated 2026 outlookJuly 23, 2026 | msn.comRoche H1 Sales Decline on Currency Headwinds, Key Drugs Keep MomentumJuly 23, 2026 | zacks.comRoche Backs Full-Year View as First-Half Sales RiseJuly 23, 2026 | wsj.comRoche confirms full year targets as first-half sales fallJuly 23, 2026 | reuters.comRoche showcases intelligent lab solutions and high-precision instruments at ADLM 2026 to help laboratories address workforce and workflow challengesJuly 22, 2026 | finance.yahoo.comRoche Appoints Dan Malarek as President and CEO of Roche Diagnostics North AmericaJuly 20, 2026 | finance.yahoo.comRoche appoints Dan Malarek as CEO of Roche Diagnostics North AmericaJuly 20, 2026 | msn.comErste Group Bank Issues Positive Outlook for Roche EarningsJuly 20, 2026 | americanbankingnews.comFY2026 EPS Estimates for Roche Lifted by Erste Group BankJuly 20, 2026 | marketbeat.comS&CO Inc. Has $6.88 Million Position in Roche Holding AG $RHHBYJuly 19, 2026 | marketbeat.comGenentech’s Gazyva receives FDA priority review for primary membranous nephropathyJuly 17, 2026 | msn.comZacks Research Downgrades Roche (OTCMKTS:RHHBY) to Strong SellJuly 16, 2026 | marketbeat.comRoche (RHHBY) Expected to Post Earnings on ThursdayJuly 16, 2026 | americanbankingnews.comRoche (RHHBY) Expected to Post Quarterly Earnings on ThursdayJuly 16, 2026 | marketbeat.comRHHBY's Gazyva Gets FDA Priority Review for Label ExpansionJuly 15, 2026 | zacks.comRoche introduces cobas Hepatitis D Virus (HDV) test, the first fully automated diagnostic solution to identify the most severe form of viral hepatitisJuly 14, 2026 | manilatimes.netMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRHHBY, NEVPF, ACUS, and ADCT Company DescriptionsAcusphere OTCMKTS:ACUSAcusphere, Inc. operates as a specialty pharmaceutical company that develops and commercializes cardiovascular drugs. It offers Imagify (perflubutane polymer microspheres), a cardiovascular drug that evaluates myocardial perfusion and detects coronary artery disease. It provides Imagify as an injectable suspension. The company was formerly known as Polymers For Medicine, Inc. and changed its name to Acusphere, Inc. in March 2004. Acusphere, Inc. was founded in 1993 and is based in Watertown, Massachusetts.ADC Therapeutics NYSE:ADCT$1.18 +0.03 (+2.17%) Closing price 07/24/2026 03:59 PM EasternExtended Trading$1.14 -0.03 (-2.55%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.Abliva AB (publ) OTCMKTS:NEVPF$0.03 0.00 (0.00%) As of 07/24/2026Abliva AB (publ), a clinical-stage biotech company, develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.Roche OTCMKTS:RHHBY$54.70 0.00 (0.00%) As of 07/24/2026 04:00 PM EasternRoche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade? Broadcom May Be the Biggest Winner From Alphabet's Earnings CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
